Arcus Biosciences, Inc.
General ticker "RCUS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.2B (TTM average)
Arcus Biosciences, Inc. follows the US Stock Market performance with the rate: 52.8%.
Estimated limits based on current volatility of 4.6%: low 21.42$, high 23.49$
Factors to consider:
- Total employees count: 627 (+8.7%) as of 2024
- Top business risk factors: Operational and conduct risks, Third-party risks, Regulatory and compliance, Labor/talent shortage/retention, Cybersecurity threats
- Current price 15.0% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [9.81$, 21.11$]
- 2025-12-31 to 2026-12-31 estimated range: [8.62$, 18.95$]
Financial Metrics affecting the RCUS estimates:
- Negative: with PPE of -5.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -12.23 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 19.35 < Shareholder equity ratio, % of 42.17 <= 42.53
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -16.21 <= 0
Short-term RCUS quotes
Long-term RCUS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $112.00MM | $117.00MM | $258.00MM |
| Operating Expenses | $392.00MM | $457.00MM | $588.00MM |
| Operating Income | $-280.00MM | $-340.00MM | $-330.00MM |
| Non-Operating Income | $14.00MM | $39.00MM | $48.00MM |
| Interest Expense | $2.00MM | $2.00MM | $4.00MM |
| R&D Expense | $288.00MM | $340.00MM | $448.00MM |
| Income(Loss) | $-266.00MM | $-301.00MM | $-282.00MM |
| Taxes | $1.00MM | $6.00MM | $1.00MM |
| Profit(Loss)* | $-267.00MM | $-307.00MM | $-282.00MM |
| Stockholders Equity | $657.00MM | $462.00MM | $485.00MM |
| Assets | $1,345.00MM | $1,095.00MM | $1,150.00MM |
| Operating Cash Flow | $438.00MM | $-306.00MM | $-170.00MM |
| Capital expenditure | $6.00MM | $24.00MM | $6.00MM |
| Investing Cash Flow | $-413.00MM | $194.00MM | $-84.00MM |
| Financing Cash Flow | $33.00MM | $33.00MM | $277.00MM |
| Earnings Per Share** | $-3.71 | $-4.15 | $-3.13 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.